Skip to main content

ENGLISH · EVIDENCE OVERVIEW

Chlorodehydromethyltestosterone / Turinabol
evidence profile

Synthetic oral anabolic-androgenic steroid. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

Chlorodehydromethyltestosterone / Turinabol: conceptual scientific illustration for Clinical / Endocrine Pharmacology
VISUAL GUIDE · Chlorodehydromethyltestosterone / Turinabol

Clinical / Endocrine Pharmacology

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

Chlorodehydromethyltestosterone / Turinabol is classified here as Synthetic oral anabolic-androgenic steroid. Historical state-doping and analytical literature do not establish a therapeutic benefit or safe modern product. No current FDA-approved human product was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.

01

ENTITY FACTS

What should readers identify first?

MOLECULEChlorodehydromethyltestosterone / Turinabol
PHARMACOLOGYSynthetic oral anabolic-androgenic steroid
PRIMECORE CLASSB
EVIDENCE GRADED
RESEARCH TOPICClinical / Endocrine Pharmacology
LAST REVIEWED2026-09-01

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

  • Chlorodehydromethyltestosterone / Turinabol molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. DEA · Steroids Drug Fact Sheet
  2. NIDA · Steroids and other APEDs
  3. WADA · 2026 Prohibited List
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Chlorodehydromethyltestosterone / Turinabol?

Chlorodehydromethyltestosterone / Turinabol is described pharmacologically as Synthetic oral anabolic-androgenic steroid. Chlorodehydromethyltestosterone / Turinabol is classified here as Synthetic oral anabolic-androgenic steroid. Historical state-doping and analytical literature do not establish a therapeutic benefit or safe modern product. No current FDA-approved human product was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.

Does Chlorodehydromethyltestosterone / Turinabol have strong evidence?

PrimeCoreBio records Evidence Grade D. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Chlorodehydromethyltestosterone / Turinabol approved everywhere?

No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice